Everest Organics Share Price
Small Cap | Pharmaceuticals and health care | BSE: 524790
₹260.00 8.45 (3.36 %)
Last Updated: 13 Mar 2025 12:00 AM
Overview
Open (₹) 256.60
High (₹) 262.00
Low (₹) 256.05
Prev. Close (₹) 251.55
Volume 5,377
VWAP (₹) 220.08
ROCE (%) 9.12
Industry P/E 43.95
TTM P/E -60.75
P/B Ratio 4.54
Market Cap (₹) Cr.252.47
Dividend Yield (%)--
EPS (₹) 0.17
ROE0.30%
Sales Growth (%) 7.75
Profit Growth (%)-176.40
Day Range
262.00262.00
52 Week Range
110.00307.15
Historical Returns
Returns (6M)
91.11 %
Returns (1Y)
117.12 %
Returns (3Y)
28.02 %
Returns (5Y)
128.07 %
Returns (6M)
91.11 %
Returns (1Y)
117.12 %
Returns (3Y)
28.02 %
Returns (5Y)
128.07 %
SWOT Analysis
- Growth in Net Profit Margin (QoQ)
- Growth in Annual Net Profit with increasing Profit Margin (YoY)
- Strong short-term momentum: Price above short-term moving averages (EMA_10)
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
RSI 46.58
MFI 67.18
ATR 16.06
Commodity Channel Index -221.70
ROC125 60.49
ROC21 -15.10
Williams %R -96.99
Resistance & Support
Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
---|---|---|---|---|---|---|---|
Current | 223.40 | 226.45 | 228.90 | 220.95 | 217.90 | 215.45 | 212.40 |
Week Ago | 256.75 | 264.70 | 275.40 | 246.05 | 238.10 | 227.40 | 219.45 |
Month Ago | 259.70 | 259.70 | 259.70 | 259.70 | 259.70 | 259.70 | 259.70 |
EMA & SMA
260.00
Current Price
Bullish Moving Averages
18
Bearish Moving Averages
2
5 Day 240.71
9 Day 243.61
10 Day 244.99
12 Day 251.38
14 Day 251.51
20 Day 253.75
26 Day 256.08
50 Day 264.30
100 Day 201.05
200 Day 170.87
Deals & Announcements
Bulk and Block Deals
Insider Trading
Date | Name | Action | Avg. Price | Quantity | Deal Value |
---|---|---|---|---|---|
05 Apr, 2023 | DR. SRIKAKARLAPUDI KRISHNAVENI | Acquisition | ₹ | 2,60,892 | BSE |
27 Mar, 2023 | DR. SRIKAKARLAPUDI KRISHNAVENI | Acquisition | ₹ | 53,135 | BSE |
23 Mar, 2023 | Srikakarlapudi Krishnaveni | Acquisition | ₹ | 53,135 | BSE |
22 Feb, 2021 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹239.00 | 1,000 | BSE |
19 Feb, 2021 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹237.22 | 2,000 | BSE |
18 Feb, 2021 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹244.61 | 2,000 | BSE |
18 Feb, 2021 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹240.60 | 2,000 | BSE |
14 Feb, 2021 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹249.10 | 2,000 | BSE |
25 Dec, 2020 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹270.70 | 500 | BSE |
24 Dec, 2020 | BK ADVANCE & RESEARCHLLP | Acquisition | ₹250.63 | 509 | BSE |
Corporate Actions
Announcement Date | Subject | Ex - Date | Record Date |
---|---|---|---|
27 May, 2022 | Rs.0.5000 per share(5%)Final Dividend | 15 Sept, 2022 | 01 Jan, 1970 |
14 Jun, 2021 | Rs.1.0000 per share(10%)Final Dividend | 08 Sept, 2021 | 01 Jan, 1970 |
08 Feb, 2021 | Rs.0.5000 per share(5%)Interim Dividend | 17 Feb, 2021 | 18 Feb, 2021 |
Announcements
Date | Source | Detail |
---|---|---|
12 Mar, 2025 | BSE India | Receipt of Listing Approval from BSE Limited |
18 Feb, 2025 | BSE India | Intimation of Korea Drug Master File (KDMF) approval for Company''s Rabeprazole Sodium API. |
13 Feb, 2025 | BSE India | Declaration of results of the postal ballot together with scrutinizers report |
13 Feb, 2025 | BSE India | Declaration of Voting Results of Postal Ballot is enclosed |
11 Feb, 2025 | BSE India | Enclosed the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024 |
11 Feb, 2025 | BSE India | Outcome of the Board Meeting held today is enclosed. |
11 Feb, 2025 | BSE India | Enclosed the Un-audited financial results for the quarter and nine months ended December 31, 2024 |
05 Feb, 2025 | BSE India | EVEREST ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve inter-alia, to transact the following item(s) of business:\r\n\r\na) to consider, approve and take on record the Un-audited financial results of the Company for the quarter and nine months ended December 31, 2024.\r\nb) to consider and take note of the limited review report of the statutory auditors of the Company for the quarter ended December 31, 2024.\r\n |
22 Jan, 2025 | BSE India | Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 |
08 Jan, 2025 | BSE India | Proceedings, Voting Results and Scrutinizer Report for the EGM held on January 08, 2025 |
Board Meetings
Purpose | Details | Meeting Date | Broadcast Date |
---|---|---|---|
Quarterly Results | -- | 06 Feb, 2025 | 11 Feb, 2025 |
Others | Inter-alia, 1. Allotment of Convertible Warrants upto 2,63,157 & Equity Shares upto 17,10,526. 2. Other business matters. | 14 Jan, 2025 | 13 Jan, 2025 |
Preferential Issue of shares | -- | 17 Dec, 2024 | 12 Dec, 2024 |
Quarterly Results | -- | 09 Nov, 2024 | 13 Nov, 2024 |
Quarterly Results | -- | 09 Aug, 2024 | 13 Aug, 2024 |
Audited Results | -- | 22 May, 2024 | 27 May, 2024 |
Quarterly Results | -- | 05 Feb, 2024 | 09 Feb, 2024 |
Quarterly Results | -- | 07 Nov, 2023 | 11 Nov, 2023 |
Quarterly Results & A.G.M. | -- | 07 Aug, 2023 | 12 Aug, 2023 |
Audited Results | -- | 22 May, 2023 | 27 May, 2023 |
Share Holding Pattern
Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
---|
About Everest Organics
Everest Organics is a Public Limited Listed company incorporated on 19/02/1993 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1993PLC015426 and registration number is 015426. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 197.24 Cr. and Equity Capital is Rs. 8.00 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1993
Managing Director
Dr. Srikakarlapudi Sirisha
NSE Symbol
--
Everest Organics Management
Name | Designation |
---|---|
Mr. Ramakrishnam Raju Kounparaju | Chairman & Ind.Director |
Dr. Srikakarlapudi Sirisha | Managing Director |
Mr. Srikakarlapudi Harikrishna | Whole Time Director |
Mr. Kakarlapudi Sitarama Raju | Non Executive Director |
Mr. Venkatasatyanarayana Murthy Chayaly | Independent Director |
Mr. Prasad Venkata Satya Sundara Srikakolapu | Independent Director |
Mr. Akella Parvathisem | Director - Technical |
Peer Comparison
Stocks | Market Cap | Market Price | 52 Week Low-High |
---|---|---|---|
Sun Pharmaceutical Industries | ₹4,03,916.05 | ₹1,683.45 ₹1,676.85(0.39%) | ₹1,376.750 - ₹1,960.200 |
Divi's Laboratories | ₹1,49,205.29 | ₹5,620.45 ₹5,667.15(-0.82%) | ₹3,350.050 - ₹6,448.750 |
Cipla | ₹1,18,065.23 | ₹1,461.90 ₹1,454.30(0.52%) | ₹1,317.600 - ₹1,702.000 |
Torrent Pharmaceuticals | ₹1,03,430.62 | ₹3,056.05 ₹3,096.50(-1.31%) | ₹2,488.000 - ₹3,589.950 |
Dr. Reddy's Laboratories | ₹92,453.48 | ₹1,107.95 ₹1,105.15(0.25%) | ₹1,093.000 - ₹1,420.200 |
FAQs on Everest Organics
What is the share price of Everest Organics?
The share price of Everest Organics on 13 Mar, 2025 is ₹ 260.00.
What is 52W high and 52W low share price of Everest Organics?
The highest and lowest 52W share prices of Everest Organics are ₹ 307.150 and ₹ 110.000
What is the market cap of Everest Organics?
The market capitalization of Everest Organics as of 13 Mar, 2025 is ₹ 252.47 Crores
What is the P/E ratio of Everest Organics?
The current P/E ratio of Everest Organics as of 13 Mar, 2025 is 43.95
What is the PB ratio of Everest Organics?
The PB ratio of Everest Organics as of 13 Mar, 2025 is 4.54
Top Gainers
₹41.02
₹34.29 (0.20%)
₹8.84
₹7.37 (0.20%)
₹6.97
₹5.81 (0.20%)
₹194.70
₹162.25 (0.20%)
Top Losers
₹13.75
₹135.15 (-0.90%)
₹9.60
₹12.00 (-0.20%)
₹9.80
₹93.55 (-0.90%)
₹0.99
₹4.77 (-0.79%)
Market Indices
Sensex
₹73,828.91
₹74,029.76 (0.00%)